Lindo Life Science
Advancing innovation in
infection control
Lindo Life Science is developing a portfolio of medical devices that are redefining how the world prevents, manages and responds to infection in critical care environments.
At the centre of this effort is Lindo Tube, which pioneers safe, light-based antimicrobial technologies to reduce healthcare-acquired infections.
Ventilator associated pneumonia (VAP) creates an economic burden of US$3 billion per year in the United States. In acute care settings, it accounts for nearly 40% of all hospital acquired pneumonia cases and remains one of the most lethal complications in hospital environments.
The Lindo Tube addresses this challenge directly. Lindo’s antimicrobial blue light system operates continuously and automatically, without the use of chemicals, additional labour or disruption to clinical workflows. The device integrates seamlessly into standard endotracheal tube assemblies, delivering targeted antimicrobial activity to reduce microbial biofilm formation with precision.
About Lindo Tube
Lindo Tube is redefining critical care. This first-in-class antimicrobial blue light (aBL) endotracheal tube is engineered to prevent ventilator-associated pneumonia (VAP) at the source.
Developed in collaboration with the Number 1 hospital in the world Mayo Clinic, Lindo Tube delivers a breakthrough solution to one of the most urgent and costly problems in healthcare.
In 2025, Lindo was awarded $2 million in matched funding under the Australian Government’s Industry Growth Program to advance the development of Lindo Tube.
This funding supports a $4 million total project value that will advance the Lindo Tube from Technology Readiness Level (TRL) 4 to TRL 7, enabling the device to enter preclinical and clinical trials in both Australia and the United States.
Advanced infection control
To find out more about Lindo Life Science or to enquire about investment opportunities, please get in touch info@lindo.group